U.S. to Provide $4 Billion for International COVID-19 Vaccine Program

FRIDAY, Feb. 19, 2021 -- The United States will soon start providing $4 billion for COVAX, an international program to buy and distribute COVID-19 vaccines to poor countries.

White House officials said President Joe Biden will make the announcement Friday at a G-7 meeting and will also encourage other members of the group to make good on their pledges to the World Health Organization initiative, the Associated Press reported.

The $4 billion in funding was approved by Congress in December and will be doled out through 2022. The United States is committed to working through COVAX to ensure "equitable distribution of vaccines and funding globally," White House Press Secretary Jen Psaki told reporters on Thursday.

The COVAX program has already missed its own goal of beginning COVID-19 vaccinations in poor countries at the same time that shots were rolled out in rich countries, the AP reported. The WHO says COVAX needs $5 billion in 2021.

U.N. Secretary-General Antonio Guterres said Wednesday that 130 countries have not received a single dose of the vaccine and declared that "at this critical moment, vaccine equity is the biggest moral test before the global community."

Associated Press Article

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Further Support and Information on COVID-19

Read this next

Physician's Briefing Weekly Coronavirus Roundup

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 16 to 19, 2021. This roundup...

Pediatric Inpatient Admissions Down During Pandemic

FRIDAY, Feb. 19, 2021 -- Inpatient pediatric admissions were down across a wide range of diagnoses during the early months of the COVID-19 pandemic, according to a study published...

Pfizer to Begin Clinical Trial of COVID-19 Vaccine in Pregnant Women

FRIDAY, Feb. 19, 2021 -- The first U.S. participants in a large-scale clinical trial to test the safety and efficacy of the Pfizer COVID-19 vaccine in pregnant women have received...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.